Pharmalot… Pharmalittle… The Weekend Nears
Make a commentBy Ed Silverman // January 21st, 2011 // 7:55 am
And so, another work week will soon draw to a close. Although once again, we are dusting off the snow on the Pharmalot corporate campus. Please excuse any delays this morning, but due to the economy, we no longer have a maintenance crew. This does give us the opportunity, though, to daydream about weekend plans - hanging out with the short people and catching up on some reading. What about you? Anything fun on the agenda? How about a good flick or spending time with someone special? Whatever you do, enjoy. Meanwhile, here are some tidbits. Catch you soon…
EMA To Review Safety Of Sanofi’s Multaq (Wall Street Journal)
AstraZeneca Responds To FDA About Brilinta (Bloomberg News)
Biogen Boosts Prices Of MS Drug (Wall Street Journal)
EU Panel Does Not Recommend Biogen MS Pill (Reuters)
EU Approves Novartis MS Gilenya Pill (Bloomberg News)
FDA Probes Seizures After Sanofi Flu Shot (Reuters)
FDA Panel Recommends Lilly Imaging Drug For Alzheimer’s (New York Times)
EU Declines To Approve Merck KGgA MS Pill (Reuters)
UK Health Secretary Asked Pharma To Accept Lower Prices (Bloomberg News)
Brand-Name Growth Will Slow To 1.5 Percent In 2015 (Datamonitor)
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Alzheimers, AstraZeneca, Biogen Idec, Bloodthinner, Brilinta, Datamonitor, Eli Lilly, EU, FDA, Flu, Gilenya, Merck KgGA, MS, Multiple Sclerosis, Novartis, Sanofi Aventis, Vaccines